
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2341281/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dysregulated Protein Phosphorylation as Main Contributor of Granulovacuolar Degeneration at the First Stages of Neurofibrillary Tangles Pathology. Neuroscience, 2023, 518, 119-140.	1.1	9
2	Tau Aggregation. Neuroscience, 2023, 518, 64-69.	1.1	20
3	Modulation of mitochondrial and inflammatory homeostasis through RIP140 is neuroprotective in an adrenoleukodystrophy mouse model. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	6
4	Expression pattern of perilipins in human brain during aging and in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	17
5	Molecular Profiles of Amyloid-β Proteoforms in Typical and Rapidly Progressive Alzheimer's Disease. Molecular Neurobiology, 2022, 59, 17-34.	1.9	8
6	Host Tau Genotype Specifically Designs and Regulates Tau Seeding and Spreading and Host Tau Transformation Following Intrahippocampal Injection of Identical Tau AD Inoculum. International Journal of Molecular Sciences, 2022, 23, 718.	1.8	7
7	Analysis of co-isogenic prion protein deficient mice reveals behavioral deficits, learning impairment, and enhanced hippocampal excitability. BMC Biology, 2022, 20, 17.	1.7	4
8	Selective brain regional changes in lipid profile with human aging. GeroScience, 2022, 44, 763-783.	2.1	15
9	Serpin Signatures in Prion and Alzheimer's Diseases. Molecular Neurobiology, 2022, 59, 3778-3799.	1.9	18
10	Differences in Tau Seeding in Newborn and Adult Wild-Type Mice. International Journal of Molecular Sciences, 2022, 23, 4789.	1.8	3
11	Dysregulated Brain Protein Phosphorylation Linked to Increased Human Tau Expression in the hTau Transgenic Mouse Model. International Journal of Molecular Sciences, 2022, 23, 6427.	1.8	1
12	The Primary Microglial Leukodystrophies: A Review. International Journal of Molecular Sciences, 2022, 23, 6341.	1.8	8
13	Differentially Aquaporin 5 Expression in Submandibular Glands and Cerebral Cortex in Alzheimer's Disease. Biomedicines, 2022, 10, 1645.	1.4	4
14	Activating cannabinoid receptor 2 preserves axonal health through GSK-3β/NRF2 axis in adrenoleukodystrophy. Acta Neuropathologica, 2022, 144, 241-258.	3.9	2
15	Lipid alterations in human frontal cortex in ALSâ€FTLDâ€TDP43 proteinopathy spectrum are partly related to peroxisome impairment. Neuropathology and Applied Neurobiology, 2021, 47, 544-563.	1.8	14
16	Cadaverine and Spermine Elicit Ca2+ Uptake in Human CP Cells via a Trace Amine-Associated Receptor 1 Dependent Pathway. Journal of Molecular Neuroscience, 2021, 71, 625-637.	1.1	2
17	TDP-43 Vasculopathy in the Spinal Cord in Sporadic Amyotrophic Lateral Sclerosis (sALS) and Frontal Cortex in sALS/FTLD-TDP. Journal of Neuropathology and Experimental Neurology, 2021, 80, 229-239.	0.9	12

#	Article	IF	CITATIONS
19	Differential astrocyte and oligodendrocyte vulnerability in murine Creutzfeldt-Jakob disease. Prion, 2021, 15, 112-120.	0.9	6
20	Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression. Brain Communications, 2021, 3, fcab143.	1.5	29
21	Neuroimmune Response Mediated by Cytokines in Natural Scrapie after Chronic Dexamethasone Treatment. Biomolecules, 2021, 11, 204.	1.8	4
22	Ecto-GPR37: a potential biomarker for Parkinson's disease. Translational Neurodegeneration, 2021, 10, 8.	3.6	19
23	Lower Locus Coeruleus MRI intensity in patients with late-life major depression. PeerJ, 2021, 9, e10828.	0.9	14
24	Prion protein oligomers cause neuronal cytoskeletal damage in rapidly progressive Alzheimer's disease. Molecular Neurodegeneration, 2021, 16, 11.	4.4	15
25	The Causal Role of Lipoxidative Damage in Mitochondrial Bioenergetic Dysfunction Linked to Alzheimer's Disease Pathology. Life, 2021, 11, 388.	1.1	16
26	TREM2 expression in the brain and biological fluids in prion diseases. Acta Neuropathologica, 2021, 141, 841-859.	3.9	18
27	Atypical astroglial pTDPâ€43 pathology in astroglial predominant tauopathy. Neuropathology and Applied Neurobiology, 2021, 47, 1109-1113.	1.8	5
28	Transcriptional signatures of synaptic vesicle genes define myotonic dystrophy type I neurodegeneration. Neuropathology and Applied Neurobiology, 2021, 47, 1092-1108.	1.8	14
29	Aberrant Synaptic PTEN in Symptomatic Alzheimer's Patients May Link Synaptic Depression to Network Failure. Frontiers in Synaptic Neuroscience, 2021, 13, 683290.	1.3	4
30	New insights into human prefrontal cortex aging with a lipidomics approach. Expert Review of Proteomics, 2021, 18, 333-344.	1.3	12
31	Tau Exon 10 Inclusion by PrPC through Downregulating GSK3Î ² Activity. International Journal of Molecular Sciences, 2021, 22, 5370.	1.8	2
32	Nuclear lipidome is altered in amyotrophic lateral sclerosis: A pilot study. Journal of Neurochemistry, 2021, 158, 482-499.	2.1	9
33	Synchrotron X-ray Fluorescence and FTIR Signatures for Amyloid Fibrillary and Nonfibrillary Plaques. ACS Chemical Neuroscience, 2021, 12, 1961-1971.	1.7	11
34	Kidins220 deficiency causes ventriculomegaly via SNX27-retromer-dependent AQP4 degradation. Molecular Psychiatry, 2021, 26, 6411-6426.	4.1	13
35	Dysregulated protein phosphorylation: A determining condition in the continuum of brain aging and Alzheimer's disease. Brain Pathology, 2021, 31, e12996.	2.1	33
36	The Structure of the Spinal Cord Ependymal Region in Adult Humans Is a Distinctive Trait among Mammals. Cells, 2021, 10, 2235.	1.8	8

#	Article	IF	CITATIONS
37	Increased YKL-40 but Not C-Reactive Protein Levels in Patients with Alzheimer's Disease. Biomedicines, 2021, 9, 1094.	1.4	8
38	Cell Stress Induces Mislocalization of Transcription Factors with Mitochondrial Enrichment. International Journal of Molecular Sciences, 2021, 22, 8853.	1.8	4
39	CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington's disease. Science Translational Medicine, 2021, 13, eabe7104.	5.8	14
40	Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer's disease. Translational Neurodegeneration, 2021, 10, 37.	3.6	8
41	proNGF Involvement in the Adult Neurogenesis Dysfunction in Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 10744.	1.8	3
42	The apolipoprotein receptor LRP3 compromises APP levels. Alzheimer's Research and Therapy, 2021, 13, 181.	3.0	9
43	Age-Related Changes in Lipidome of Rat Frontal Cortex and Cerebellum Are Partially Reversed by Methionine Restriction Applied in Old Age. International Journal of Molecular Sciences, 2021, 22, 12517.	1.8	8
44	Relevance of host tau in tau seeding and spreading in tauopathies. Brain Pathology, 2020, 30, 298-318.	2.1	22
45	Cannabidiol-Enriched Extract Reduced the Cognitive Impairment but Not the Epileptic Seizures in a Lafora Disease Animal Model. Cannabis and Cannabinoid Research, 2020, 5, 150-163.	1.5	13
46	Familial globular glial tauopathy linked to MAPT mutations: molecular neuropathology and seeding capacity of a prototypical mixed neuronal and glial tauopathy. Acta Neuropathologica, 2020, 139, 735-771.	3.9	35
47	Gender-Specific Beneficial Effects of Docosahexaenoic Acid Dietary Supplementation in G93A-SOD1 Amyotrophic Lateral Sclerosis Mice. Neurotherapeutics, 2020, 17, 269-281.	2.1	15
48	The clinical and radiological profile of primary lateral sclerosis: an annotation on its pathological and clinical background. Journal of Neurology, 2020, 267, 574-574.	1.8	1
49	Potential of Microfluidics and Lab-on-Chip Platforms to Improve Understanding of "prion-like― Protein Assembly and Behavior. Frontiers in Bioengineering and Biotechnology, 2020, 8, 570692.	2.0	5
50	Tau Protein as a New Regulator of Cellular Prion Protein Transcription. Molecular Neurobiology, 2020, 57, 4170-4186.	1.9	6
51	Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2020, 21, 8680.	1.8	13
52	The Presence of Human Herpesvirus 6 in the Brain in Health and Disease. Biomolecules, 2020, 10, 1520.	1.8	24
53	Amyotrophic Lateral Sclerosis Is Accompanied by Protein Derangements in the Olfactory Bulb-Tract Axis. International Journal of Molecular Sciences, 2020, 21, 8311.	1.8	11
54	Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6. Journal of Medicinal Chemistry, 2020, 63, 9360-9390.	2.9	25

#	Article	IF	CITATIONS
55	Locus coeruleus connectivity alterations in late-life major depressive disorder during a visual oddball task. NeuroImage: Clinical, 2020, 28, 102482.	1.4	14
56	Assessment of Glial Activation Response in the Progress of Natural Scrapie after Chronic Dexamethasone Treatment. International Journal of Molecular Sciences, 2020, 21, 3231.	1.8	9
57	Annexin A5 prevents amyloid-β-induced toxicity in choroid plexus: implication for Alzheimer's disease. Scientific Reports, 2020, 10, 9391.	1.6	18
58	Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations. PLoS ONE, 2020, 15, e0233468.	1.1	29
59	Highâ€dose biotin restores redox balance, energy and lipid homeostasis, and axonal health in a model of adrenoleukodystrophy. Brain Pathology, 2020, 30, 945-963.	2.1	11
60	Succination of Protein Thiols in Human Brain Aging. Frontiers in Aging Neuroscience, 2020, 12, 52.	1.7	10
61	Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1 \hat{i} kinase inhibitor treatment. Scientific Reports, 2020, 10, 4449.	1.6	44
62	The Quest for Cellular Prion Protein Functions in the Aged and Neurodegenerating Brain. Cells, 2020, 9, 591.	1.8	14
63	Capacity for Seeding and Spreading of Argyrophilic Grain Disease in a Wild-Type Murine Model; Comparisons With Primary Age-Related Tauopathy. Frontiers in Molecular Neuroscience, 2020, 13, 101.	1.4	8
64	SFPQ and Tau: critical factors contributing to rapid progression of Alzheimer's disease. Acta Neuropathologica, 2020, 140, 317-339.	3.9	45
65	Calcium-binding proteins are altered in the cerebellum in schizophrenia. PLoS ONE, 2020, 15, e0230400.	1.1	16
66	Disrupted functional connectivity of the locus coeruleus in healthy adults with parental history of Alzheimer's disease. Journal of Psychiatric Research, 2020, 123, 81-88.	1.5	16
67	Diagnostic Accuracy of Prion Disease Biomarkers in latrogenic Creutzfeldt-Jakob Disease. Biomolecules, 2020, 10, 290.	1.8	10
68	Bitter taste receptors profiling in the human blood-cerebrospinal fluid-barrier. Biochemical Pharmacology, 2020, 177, 113954.	2.0	11
69	White matter alterations in Alzheimer's disease without concomitant pathologies. Neuropathology and Applied Neurobiology, 2020, 46, 654-672.	1.8	24
70	Selected cryptic exons accumulate in hippocampal cell nuclei in Alzheimer's disease with and without associated TDP-43 proteinopathy. Brain, 2020, 143, e20-e20.	3.7	5
71	Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. Nature Communications, 2020, 11, 619.	5.8	67
72	CpG and non-CpG Presenilin1 methylation pattern in course of neurodevelopment and neurodegeneration is associated with gene expression in human and murine brain. Epigenetics, 2020, 15, 781-799.	1.3	39

#	Article	IF	CITATIONS
73	Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases. Cells, 2020, 9, 1252.	1.8	8
74	Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations. , 2020, 15, e0233468.		0
75	Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations. , 2020, 15, e0233468.		Ο
76	Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations. , 2020, 15, e0233468.		0
77	Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations. , 2020, 15, e0233468.		Ο
78	Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases. Molecular Neurobiology, 2019, 56, 2811-2821.	1.9	20
79	Differences in structure and function between human and murine tau. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2024-2030.	1.8	22
80	Early-Onset Molecular Derangements in the Olfactory Bulb of Tg2576 Mice: Novel Insights Into the Stress-Responsive Olfactory Kinase Dynamics in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2019, 11, 141.	1.7	12
81	Plasma YKL-40 in the spectrum of neurodegenerative dementia. Journal of Neuroinflammation, 2019, 16, 145.	3.1	40
82	Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis. Nature Neuroscience, 2019, 22, 1258-1268.	7.1	48
83	Revealing Adenosine A2A-Dopamine D2 Receptor Heteromers in Parkinson's Disease Post-Mortem Brain through a New AlphaScreen-Based Assay. International Journal of Molecular Sciences, 2019, 20, 3600.	1.8	40
84	Historical setting and neuropathology of lathyrism: Insights from the neglected 1944 report by Oliveras de la Riva. Journal of the History of the Neurosciences, 2019, 28, 361-386.	0.1	5
85	Synthesis, In Vitro Profiling, and In Vivo Efficacy Studies of a New Family of Multitarget Anti-Alzheimer Compounds. Proceedings (mdpi), 2019, 22, .	0.2	Ο
86	Role of tau N-terminal motif in the secretion of human tau by End Binding proteins. PLoS ONE, 2019, 14, e0210864.	1.1	31
87	Poly(propylene imine) dendrimers with histidine-maltose shell as novel type of nanoparticles for synapse and memory protection. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 17, 198-209.	1.7	75
88	Involvement of Oligodendrocytes in Tau Seeding and Spreading in Tauopathies. Frontiers in Aging Neuroscience, 2019, 11, 112.	1.7	46
89	Globular glial tauopathy caused by MAPT P301T mutation: clinical and neuropathological findings. Journal of Neurology, 2019, 266, 2396-2405.	1.8	22
90	Mutations in <i>TIMM50</i> cause severe mitochondrial dysfunction by targeting key aspects of mitochondrial physiology. Human Mutation, 2019, 40, 1700-1712.	1.1	16

#	Article	IF	CITATIONS
91	Hereditary primary lateral sclerosis and progressive nonfluent aphasia. Journal of Neurology, 2019, 266, 1079-1090.	1.8	21
92	Redox lipidomics to better understand brain aging and function. Free Radical Biology and Medicine, 2019, 144, 310-321.	1.3	28
93	Myoglobinopathy is an adult-onset autosomal dominant myopathy with characteristic sarcoplasmic inclusions. Nature Communications, 2019, 10, 1396.	5.8	11
94	Combined Transcriptomics and Proteomics in Frontal Cortex Area 8 in Frontotemporal Lobar Degeneration Linked to C9ORF72 Expansion. Journal of Alzheimer's Disease, 2019, 68, 1287-1307.	1.2	14
95	Wnt Signaling Alterations in the Human Spinal Cord of Amyotrophic Lateral Sclerosis Cases: Spotlight on Fz2 and Wnt5a. Molecular Neurobiology, 2019, 56, 6777-6791.	1.9	26
96	Differential Aggregation and Phosphorylation of Alpha Synuclein in Membrane Compartments Associated With Parkinson Disease. Frontiers in Neuroscience, 2019, 13, 382.	1.4	34
97	Altered Dynein Axonemal Assembly Factor 1 Expression in C-Boutons in Bulbar and Spinal Cord Motor-Neurons in Sporadic Amyotrophic Lateral Sclerosis. Journal of Neuropathology and Experimental Neurology, 2019, 78, 416-425.	0.9	5
98	RNA editing alterations define manifestation of prion diseases. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 19727-19735.	3.3	17
99	Nuclear localization and phosphorylation modulate pathological effects of alpha-synuclein. Human Molecular Genetics, 2019, 28, 31-50.	1.4	131
100	Lipids and lipoxidation in human brain aging. Mitochondrial ATP-synthase as a key lipoxidation target. Redox Biology, 2019, 23, 101082.	3.9	52
101	Neuroinflammation in the dorsolateral prefrontal cortex in elderly chronic schizophrenia. European Neuropsychopharmacology, 2019, 29, 384-396.	0.3	34
102	Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob disease. Journal of Clinical Neuroscience, 2019, 60, 124-127.	0.8	18
103	Unveiling the olfactory proteostatic disarrangement in Parkinson's disease by proteome-wide profiling. Neurobiology of Aging, 2019, 73, 123-134.	1.5	48
104	Lipid Profile in Human Frontal Cortex is Sustained Throughout Healthy Adult Lifespan to Decay at Advanced Ages. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 703-710.	1.7	13
105	Role of cellular prion protein in interneuronal amyloid transmission. Progress in Neurobiology, 2018, 165-167, 87-102.	2.8	22
106	Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimer's and Dementia, 2018, 14, 751-763.	0.4	61
107	Agingâ€related tau astrogliopathy (ARTAG): not only tau phosphorylation in astrocytes. Brain Pathology, 2018, 28, 965-985.	2.1	59
108	Purineâ€related metabolites and their converting enzymes are altered in frontal, parietal and temporal cortex at early stages of Alzheimer's disease pathology. Brain Pathology, 2018, 28, 933-946.	2.1	59

#	Article	IF	CITATIONS
109	Hippocampal Radial Glial Subtypes and Their Neurogenic Potential in Human Fetuses and Healthy and Alzheimer's Disease Adults. Cerebral Cortex, 2018, 28, 2458-2478.	1.6	128
110	"Lipid raft aging―in the human frontal cortex during nonpathological aging: gender influences and potential implicationsÂin Alzheimer's disease. Neurobiology of Aging, 2018, 67, 42-52.	1.5	64
111	Mitochondrial activity in the frontal cortex area 8 and angular gyrus in <scp>P</scp> arkinson's disease and <scp>P</scp> arkinson's disease with dementia. Brain Pathology, 2018, 28, 43-57.	2.1	27
112	Molecular Alterations in the Cerebellum of Sporadic Creutzfeldt–Jakob Disease Subtypes with DJ-1 as a Key Regulator of Oxidative Stress. Molecular Neurobiology, 2018, 55, 517-537.	1.9	11
113	Involvement of Cellular Prion Protein in α-Synuclein Transport in Neurons. Molecular Neurobiology, 2018, 55, 1847-1860.	1.9	55
114	Transcriptional network analysis in frontal cortex in <scp>L</scp> ewy body diseases with focus on dementia with <scp>L</scp> ewy bodies. Brain Pathology, 2018, 28, 315-333.	2.1	35
115	iPS Cell Cultures from a Gerstmann-StrÃ ¤ ssler-Scheinker Patient with the Y218N PRNP Mutation Recapitulate tau Pathology. Molecular Neurobiology, 2018, 55, 3033-3048.	1.9	27
116	Sisyphus in Neverland. Journal of Alzheimer's Disease, 2018, 62, 1023-1047.	1.2	0
117	Neuropathology of cerebrovascular diseases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 79-114.	1.0	36
118	Astrogliopathy in Tauopathies. Neuroglia (Basel, Switzerland), 2018, 1, 126-150.	0.3	24
119	YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression. Aging, 2018, 10, 2367-2382.	1.4	25
120	proBDNF is modified by advanced glycation end products in Alzheimer's disease and causes neuronal apoptosis by inducing p75 neurotrophin receptor processing. Molecular Brain, 2018, 11, 68.	1.3	79
121	PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies. International Journal of Nanomedicine, 2018, Volume 13, 5577-5590.	3.3	52
122	MicroRNA Alterations in the Brain and Body Fluids of Humans and Animal Prion Disease Models: Current Status and Perspectives. Frontiers in Aging Neuroscience, 2018, 10, 220.	1.7	18
123	Gene Expression Profile in Frontal Cortex in Sporadic Frontotemporal Lobar Degeneration-TDP. Journal of Neuropathology and Experimental Neurology, 2018, 77, 608-627.	0.9	15
124	Proteomics and lipidomics in the human brain. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 150, 285-302.	1.0	7
125	Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. Autophagy, 2018, 14, 1404-1418.	4.3	87
126	Decreased generation of Câ€ŧerminal fragments of ApoER2 and increased reelin expression in Alzheimer's disease. FASEB Journal, 2018, 32, 3536-3546.	0.2	23

#	Article	IF	CITATIONS
127	Oligodendrogliopathy in neurodegenerative diseases with abnormal protein aggregates: The forgotten partner. Progress in Neurobiology, 2018, 169, 24-54.	2.8	49
128	Regional vulnerability to lipoxidative damage and inflammation in normal human brain aging. Experimental Gerontology, 2018, 111, 218-228.	1.2	22
129	Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies. Frontiers in Aging Neuroscience, 2018, 10, 122.	1.7	38
130	Altered Regulation of KIAA0566, and Katanin Signaling Expression in the Locus Coeruleus With Neurofibrillary Tangle Pathology. Frontiers in Cellular Neuroscience, 2018, 12, 131.	1.8	13
131	Hemoglobin mRNA Changes in the Frontal Cortex of Patients with Neurodegenerative Diseases. Frontiers in Neuroscience, 2018, 12, 8.	1.4	26
132	Altered gene transcription linked to astrocytes and oligodendrocytes in frontal cortex in Creutzfeldt-Jakob disease. Prion, 2018, 12, 216-225.	0.9	13
133	Aberrant regulation of the <scp>CSK</scp> â€3β/ <scp>NRF</scp> 2 axis unveils a novel therapy for adrenoleukodystrophy. EMBO Molecular Medicine, 2018, 10, .	3.3	35
134	PM20D1 is aÂquantitative trait locus associated with Alzheimer's disease. Nature Medicine, 2018, 24, 598-603.	15.2	73
135	Sporadic Creutzfeldt–Jakob disease with glial PrP ^{Res} nuclear and perinuclear immunoreactivity. Neuropathology, 2018, 38, 561-567.	0.7	3
136	Genetic deletion of CB1 cannabinoid receptors exacerbates the Alzheimer-like symptoms in a transgenic animal model. Biochemical Pharmacology, 2018, 157, 210-216.	2.0	32
137	The human brainome: network analysis identifies HSPA2 as a novel Alzheimer's disease target. Brain, 2018, 141, 2721-2739.	3.7	31
138	Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. Biochemical Pharmacology, 2018, 157, 67-84.	2.0	75
139	Cryptic exon splicing function of TARDBP interacts with autophagy in nervous tissue. Autophagy, 2018, 14, 1398-1403.	4.3	39
140	Cytoskeleton-Associated Risk Modifiers Involved in Early and Rapid Progression of Sporadic Creutzfeldt-Jakob Disease. Molecular Neurobiology, 2018, 55, 4009-4029.	1.9	11
141	Regional and subtype-dependent miRNA signatures in sporadic Creutzfeldt-Jakob disease are accompanied by alterations in miRNA silencing machinery and biogenesis. PLoS Pathogens, 2018, 14, e1006802.	2.1	26
142	Strain-Specific Altered Regulatory Response of Rab7a and Tau in Creutzfeldt-Jakob Disease and Alzheimer's Disease. Molecular Neurobiology, 2017, 54, 697-709.	1.9	23
143	Hereditary Human Prion Diseases: an Update. Molecular Neurobiology, 2017, 54, 4138-4149.	1.9	69
144	Inflammation in Lafora Disease: Evolution with Disease Progression in Laforin and Malin Knock-out Mouse Models. Molecular Neurobiology, 2017, 54, 3119-3130.	1.9	53

#	Article	IF	CITATIONS
145	Fatal familial insomnia: mitochondrial and protein synthesis machinery decline in the mediodorsal thalamus. Brain Pathology, 2017, 27, 95-106.	2.1	26
146	DNA Methylation Profiles of Selected Pro-Inflammatory Cytokines in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2017, 76, nlw099.	0.9	44
147	Whole genome grey and white matter DNA methylation profiles in dorsolateral prefrontal cortex. Synapse, 2017, 71, e21959.	0.6	13
148	Locus coeruleus at asymptomatic early and middle Braak stages of neurofibrillary tangle pathology. Neuropathology and Applied Neurobiology, 2017, 43, 373-392.	1.8	72
149	Region-specific vulnerability to lipid peroxidation and evidence of neuronal mechanisms for polyunsaturated fatty acid biosynthesis in the healthy adult human central nervous system. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2017, 1862, 485-495.	1.2	49
150	Imaging mass spectrometry (IMS) of cortical lipids from preclinical to severe stages of Alzheimer's disease. Biochimica Et Biophysica Acta - Biomembranes, 2017, 1859, 1604-1614.	1.4	52
151	Biomonitorization of iron accumulation in the substantia nigra from Lewy body disease patients. Toxicology Reports, 2017, 4, 188-193.	1.6	20
152	Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG). Journal of Neuropathology and Experimental Neurology, 2017, 76, 605-619.	0.9	38
153	Fatal Familial Insomnia: Clinical Aspects and Molecular Alterations. Current Neurology and Neuroscience Reports, 2017, 17, 30.	2.0	33
154	Sixty years old is the breakpoint of human frontal cortex aging. Free Radical Biology and Medicine, 2017, 103, 14-22.	1.3	32
155	Tauroursodeoxycholic bile acid arrests axonal degeneration by inhibiting the unfolded protein response in X-linked adrenoleukodystrophy. Acta Neuropathologica, 2017, 133, 283-301.	3.9	43
156	Aging dependent effect of nuclear tau. Brain Research, 2017, 1677, 129-137.	1.1	37
157	Loss of <scp>SIRT</scp> 2 leads to axonal degeneration and locomotor disability associated with redox and energy imbalance. Aging Cell, 2017, 16, 1404-1413.	3.0	36
158	Olfactory bulb neuroproteomics reveals a chronological perturbation of survival routes and a disruption of prohibitin complex during Alzheimer's disease progression. Scientific Reports, 2017, 7, 9115.	1.6	73
159	MicroRNA Expression in the Locus Coeruleus, Entorhinal Cortex, and Hippocampus at Early and Middle Stages of Braak Neurofibrillary Tangle Pathology. Journal of Molecular Neuroscience, 2017, 63, 206-215.	1.1	18
160	The cellular prion protein (PrP ^C) as neuronal receptor for α-synuclein. Prion, 2017, 11, 226-233.	0.9	29
161	Diversity of astroglial responses across human neurodegenerative disorders and brain aging. Brain Pathology, 2017, 27, 645-674.	2.1	109
162	Regional Gene Expression of Inflammation and Oxidative Stress Responses Does Not Predict Neurodegeneration in Aging. Journal of Neuropathology and Experimental Neurology, 2017, 76, 135-150.	0.9	7

#	Article	IF	CITATIONS
163	Differential overexpression of SERPINA3 in human prion diseases. Scientific Reports, 2017, 7, 15637.	1.6	58
164	The serine protease inhibitor neuroserpin is required for normal synaptic plasticity and regulates learning and social behavior. Learning and Memory, 2017, 24, 650-659.	0.5	24
165	Altered Ca2+ homeostasis induces Calpain-Cathepsin axis activation in sporadic Creutzfeldt-Jakob disease. Acta Neuropathologica Communications, 2017, 5, 35.	2.4	31
166	Anomalies occurring in lipid profiles and protein distribution in frontal cortex lipid rafts in dementia with Lewy bodies disclose neurochemical traits partially shared by Alzheimer's and Parkinson's diseases. Neurobiology of Aging, 2017, 49, 52-59.	1.5	48
167	Wnts Are Expressed in the Ependymal Region of the Adult Spinal Cord. Molecular Neurobiology, 2017, 54, 6342-6355.	1.9	13
168	Reelin Expression in Creutzfeldt-Jakob Disease and Experimental Models of Transmissible Spongiform Encephalopathies. Molecular Neurobiology, 2017, 54, 6412-6425.	1.9	2
169	Prion Protein Interactome: Identifying Novel Targets in Slowly and Rapidly Progressive Forms of Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 265-275.	1.2	17
170	Lipid raft ER signalosome malfunctions in menopause and Alzheimer rsquo s disease. Frontiers in Bioscience - Scholar, 2017, 9, 111-126.	0.8	31
171	Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms. Frontiers in Neurology, 2017, 8, 89.	1.1	35
172	Inflammatory Gene Expression in Whole Peripheral Blood at Early Stages of Sporadic Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2017, 8, 546.	1.1	26
173	YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Molecular Neurodegeneration, 2017, 12, 83.	4.4	140
174	Amyotrophic lateral sclerosis, gene deregulation in the anterior horn of the spinal cord and frontal cortex area 8: implications in frontotemporal lobar degeneration. Aging, 2017, 9, 823-851.	1.4	50
175	GSK3β 5'-flanking DNA Methylation and Expression in Alzheimer's Disease Patients. Current Alzheimer Research, 2017, 14, 753-759.	0.7	20
176	Reduced Mitochondrial Activity is Early and Steady in the Entorhinal Cortex but it is Mainly Unmodified in the Frontal Cortex in Alzheimer's Disease. Current Alzheimer Research, 2017, 14, 1327-1334.	0.7	36
177	Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease. Current Alzheimer Research, 2017, 14, 1305-1317.	0.7	69
178	Specific Metabolomics Adaptations Define a Differential Regional Vulnerability in the Adult Human Cerebral Cortex. Frontiers in Molecular Neuroscience, 2016, 9, 138.	1.4	17
179	Olfactory Receptors in Non-Chemosensory Organs: The Nervous System in Health and Disease. Frontiers in Aging Neuroscience, 2016, 8, 163.	1.7	86
180	CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease. Frontiers in Neuroscience, 2016, 10, 243.	1.4	92

#	Article	IF	CITATIONS
181	Genetic and Transcriptomic Profiles of Inflammation in Neurodegenerative Diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and Tauopathies. International Journal of Molecular Sciences, 2016, 17, 206.	1.8	91
182	Iron overload causes endolysosomal deficits modulated by NAADP-regulated 2-pore channels and RAB7A. Autophagy, 2016, 12, 1487-1506.	4.3	37
183	Altered Machinery of Protein Synthesis in Alzheimer's: From the Nucleolus to the Ribosome. Brain Pathology, 2016, 26, 593-605.	2.1	180
184	Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine. Journal of Alzheimer's Disease, 2016, 51, 489-500.	1.2	56
185	Kidins220 Correlates with Tau inÂAlzheimer's Disease Brain andÂCerebrospinal Fluid. Journal of Alzheimer's Disease, 2016, 55, 1327-1333.	1.2	7
186	Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model. Journal of Alzheimer's Disease, 2016, 54, 903-912.	1.2	49
187	Identification of new molecular alterations in fatal familial insomnia. Human Molecular Genetics, 2016, 25, ddw108.	1.4	21
188	Familial early-onset dementia with complex neuropathologic phenotype and genomic background. Neurobiology of Aging, 2016, 42, 199-204.	1.5	16
189	The glial phosphorylase of glycogen isoform is reduced in the dorsolateral prefrontal cortex in chronic schizophrenia. Schizophrenia Research, 2016, 177, 37-43.	1.1	20
190	Amyloid-β Precursor Protein Modulates the Sorting of Testican-1 and Contributes to Its Accumulation in Brain Tissue and Cerebrospinal Fluid from Patients with Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2016, 75, 903-916.	0.9	18
191	Potential Role of Aminoprocalcitonin in the Pathogenesis of Alzheimer Disease. American Journal of Pathology, 2016, 186, 2723-2735.	1.9	5
192	Incidental corticobasal degeneration. Neuropathology and Applied Neurobiology, 2016, 42, 659-663.	1.8	7
193	Miniâ€symposium: Huntington's disease ―introduction. Brain Pathology, 2016, 26, 724-725.	2.1	Ο
194	An early dysregulation of FAK and MEK/ERK signaling pathways precedes the β-amyloid deposition in the olfactory bulb of APP/PS1 mouse model of Alzheimer's disease. Journal of Proteomics, 2016, 148, 149-158.	1.2	56
195	CB1 cannabinoid receptor enrichment in the ependymal region of the adult human spinal cord. Scientific Reports, 2016, 5, 17745.	1.6	10
196	FOXP2 Expression in Frontotemporal Lobar Degeneration-Tau. Journal of Alzheimer's Disease, 2016, 54, 471-475.	1.2	3
197	Early and gender-specific differences in spinal cord mitochondrial function and oxidative stress markers in a mouse model of ALS. Acta Neuropathologica Communications, 2016, 4, 3.	2.4	43
198	Altered CSNK1E, FABP4 and NEFH protein levels in the dorsolateral prefrontal cortex in schizophrenia. Schizophrenia Research, 2016, 177, 88-97.	1.1	26

#	Article	IF	CITATIONS
199	Altered Mitochondria, Protein Synthesis Machinery, and Purine Metabolism Are Molecular Contributors to the Pathogenesis of Creutzfeldt–Jakob Disease. Journal of Neuropathology and Experimental Neurology, 2016, 75, 755-769.	0.9	21
200	Sporadic adultâ€onset leucodystrophy with axonal spheroids and pigmented glia with no mutations in the known targeted genes. Histopathology, 2016, 68, 308-312.	1.6	10
201	Interplay between TDP-43 and docosahexaenoic acid-related processes in amyotrophic lateral sclerosis. Neurobiology of Disease, 2016, 88, 148-160.	2.1	27
202	Human DNA methylomes of neurodegenerative diseases show common epigenomic patterns. Translational Psychiatry, 2016, 6, e718-e718.	2.4	137
203	Altered Mitochondrial DNA Methylation Pattern inÂAlzheimer Disease–Related Pathology and in Parkinson Disease. American Journal of Pathology, 2016, 186, 385-397.	1.9	150
204	Limited Unfolded Protein Response and Inflammation in Neuroserpinopathy. Journal of Neuropathology and Experimental Neurology, 2016, 75, 121-133.	0.9	8
205	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 2016, 131, 87-102.	3.9	380
206	CSF biomarkers in neurodegenerative and vascular dementias. Progress in Neurobiology, 2016, 138-140, 36-53.	2.8	34
207	Redox proteomic profiling of neuroketal-adducted proteins in human brain: Regional vulnerability at middle age increases in the elderly. Free Radical Biology and Medicine, 2016, 95, 1-15.	1.3	28
208	Impaired PLP-dependent metabolism in brain samples from Huntington disease patients and transgenic R6/1 mice. Metabolic Brain Disease, 2016, 31, 579-586.	1.4	7
209	Specific small-RNA signatures in the amygdala at premotor and motor stages of Parkinson's disease revealed by deep sequencing analysis. Bioinformatics, 2016, 32, 673-681.	1.8	29
210	Regulation of human cerebrospinal fluid malate dehydrogenase 1 in sporadic Creutzfeldt-Jakob disease patients. Aging, 2016, 8, 2927-2935.	1.4	13
211	(Pathoâ€)physiological relevance of <scp>PINK</scp> 1â€dependent ubiquitin phosphorylation. EMBO Reports, 2015, 16, 1114-1130.	2.0	147
212	Altered machinery of protein synthesis is region- and stage-dependent and is associated with α-synuclein oligomers in Parkinson's disease. Acta Neuropathologica Communications, 2015, 3, 76.	2.4	87
213	Purine metabolism gene deregulation in <scp>P</scp> arkinson's disease. Neuropathology and Applied Neurobiology, 2015, 41, 926-940.	1.8	59
214	Fibrinogen-Derived γ377–395 Peptide Improves Cognitive Performance and Reduces Amyloid-β Deposition, without Altering Inflammation, in AβPP/PS1 Mice. Journal of Alzheimer's Disease, 2015, 47, 403-412.	1.2	6
215	Abnormal Expression and Distribution of MMP2 at Initial Stages of Alzheimer's Disease-Related Pathology. Journal of Alzheimer's Disease, 2015, 46, 461-469.	1.2	27
216	Memory Improvement in the AÎ ² PP/PS1 Mouse Model of Familial Alzheimer's Disease Induced by Carbamylated-Erythropoietin is Accompanied by Modulation of Synaptic Genes. Journal of Alzheimer's Disease, 2015, 45, 407-421.	1.2	30

#	Article	IF	CITATIONS
217	Olfactory bulb proteome dynamics during the progression of sporadic Alzheimer's disease: identification of common and distinct olfactory targets across Alzheimer-related co-pathologies. Oncotarget, 2015, 6, 39437-39456.	0.8	66
218	Complex Inflammation mRNA-Related Response in ALS Is Region Dependent. Neural Plasticity, 2015, 2015, 1-11.	1.0	25
219	The ependymal region of the adult human spinal cord differs from other species and shows ependymoma-like features. Brain, 2015, 138, 1583-1597.	3.7	48
220	Clinical Correlations With Lewy Body Pathology in <i>LRRK2</i> -Related Parkinson Disease. JAMA Neurology, 2015, 72, 100.	4.5	272
221	Selection of controls in the study of human neurodegenerative diseases in old age. Journal of Neural Transmission, 2015, 122, 941-947.	1.4	10
222	High-fat diet-induced deregulation of hippocampal insulin signaling and mitochondrial homeostasis deficiences contribute to Alzheimer disease pathology in rodents. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 1687-1699.	1.8	134
223	Neuroinflammatory Gene Regulation, Mitochondrial Function, Oxidative Stress, and Brain Lipid Modifications With Disease Progression in Tau P301S Transgenic Mice as a Model of Frontotemporal Lobar Degeneration-Tau. Journal of Neuropathology and Experimental Neurology, 2015, 74, 975-999.	0.9	55
224	Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion. Cell Cycle, 2015, 14, 3644-3655.	1.3	19
225	Autophagy induction halts axonal degeneration in a mouse model of X-adrenoleukodystrophy. Acta Neuropathologica, 2015, 129, 399-415.	3.9	39
226	Novel Levetiracetam Derivatives That Are Effective against the Alzheimer-like Phenotype in Mice: Synthesis, in Vitro, ex Vivo, and in Vivo Efficacy Studies. Journal of Medicinal Chemistry, 2015, 58, 6018-6032.	2.9	58
227	Lipidomics of Human Brain Aging and Alzheimer's Disease Pathology. International Review of Neurobiology, 2015, 122, 133-189.	0.9	139
228	Proteome-wide characterization of signalling interactions in the hippocampal CA4/DG subfield of patients with Alzheimer's disease. Scientific Reports, 2015, 5, 11138.	1.6	54
229	Involvement of PrPC in kainate-induced excitotoxicity in several mouse strains. Scientific Reports, 2015, 5, 11971.	1.6	32
230	Oxidative stress, mitochondrial and proteostasis malfunction in adrenoleukodystrophy: A paradigm for axonal degeneration. Free Radical Biology and Medicine, 2015, 88, 18-29.	1.3	54
231	Creutzfeldt-Jakob Disease Subtype-Specific Regional and Temporal Regulation of ADP Ribosylation Factor-1-Dependent Rho/MLC Pathway at Pre-Clinical Stage. Journal of Molecular Neuroscience, 2015, 56, 329-348.	1.1	7
232	Anatomical location of <scp>LPA</scp> ₁ activation and <scp>LPA</scp> phospholipid precursors in rodent and human brain. Journal of Neurochemistry, 2015, 134, 471-485.	2.1	20
233	Mutation loads in different tissues from six pathogenic mtDNA point mutations. Mitochondrion, 2015, 22, 17-22.	1.6	15
234	Familial Behavioral Variant Frontotemporal Dementia Associated With Astrocyte-Predominant Tauopathy. Journal of Neuropathology and Experimental Neurology, 2015, 74, 370-379.	0.9	37

#	Article	IF	CITATIONS
235	Neuroinflammatory Signals in Alzheimer Disease and APP/PS1 Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 2015, 74, 319-344.	0.9	105
236	Expression of Regulatory Proteins in Choroid Plexus Changes in Early Stages of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2015, 74, 359-369.	0.9	17
237	Activation of sirtuin 1 as therapy for the peroxisomal disease adrenoleukodystrophy. Cell Death and Differentiation, 2015, 22, 1742-1753.	5.0	27
238	Decrease in olfactory and taste receptor expression in the dorsolateral prefrontal cortex in chronic schizophrenia. Journal of Psychiatric Research, 2015, 60, 109-116.	1.5	57
239	Role of PrPC Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution. Molecular Neurobiology, 2015, 51, 1206-1220.	1.9	25
240	Deregulation of purine metabolism in Alzheimer's disease. Neurobiology of Aging, 2015, 36, 68-80.	1.5	108
241	Subtype and regional regulation of prion biomarkers in sporadic <scp>C</scp> reutzfeldt– <scp>J</scp> akob disease. Neuropathology and Applied Neurobiology, 2015, 41, 631-645.	1.8	24
242	Disclosing Bias in Bisulfite Assay: MethPrimers Underestimate High DNA Methylation. PLoS ONE, 2015, 10, e0118318.	1.1	42
243	Cannabinoids for treatment of Alzheimerââ,¬â"¢s disease: moving toward the clinic. Frontiers in Pharmacology, 2014, 5, 37.	1.6	166
244	Subtype and Regional-Specific Neuroinflammation in Sporadic Creutzfeldtââ,¬â€œJakob Disease. Frontiers in Aging Neuroscience, 2014, 6, 198.	1.7	63
245	P2-013: ANNEXIN V INHIBITS Î ² -AMYLOID-INDUCED CITOTOXITY IN CHOROID PLEXUS: IMPLICATIONS FOR ALZHEIMER'S DISEASE. , 2014, 10, P475-P475.		0
246	Disrupting MLC1 and GlialCAM and ClC-2 interactions in leukodystrophy entails glial chloride channel dysfunction. Nature Communications, 2014, 5, 3475.	5.8	92
247	α <scp>B</scp> â€crystallin and <scp>HSP27</scp> in glial cells in tauopathies. Neuropathology, 2014, 34, 517-526.	0.7	16
248	Aβ promotes VDAC1 channel dephosphorylation in neuronal lipid rafts. Relevance to the mechanisms of neurotoxicity in Alzheimer's disease. Neuroscience, 2014, 278, 354-366.	1.1	38
249	Neuroprotective Role of Trans-Resveratrol in a Murine Model of Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 1209-1220.	1.2	141
250	Metabolomics of Human Brain Aging and Age-Related Neurodegenerative Diseases. Journal of Neuropathology and Experimental Neurology, 2014, 73, 640-657.	0.9	174
251	Mesencephalic dopaminergic neurons express a repertoire of olfactory receptors and respond to odorant-like molecules. BMC Genomics, 2014, 15, 729.	1.2	46
252	Glial and Neuronal Tau Pathology in Tauopathies. Journal of Neuropathology and Experimental Neurology, 2014, 73, 81-97.	0.9	174

#	Article	IF	CITATIONS
253	Reduced striatal adenosine A2A receptor levels define a molecular subgroup in schizophrenia. Journal of Psychiatric Research, 2014, 51, 49-59.	1.5	41
254	Gene Expression Resulting from PrPC Ablation and PrPC Overexpression in Murine and Cellular Models. Molecular Neurobiology, 2014, 49, 413-423.	1.9	7
255	Complex Deregulation and Expression of Cytokines and Mediators of the Immune Response in <scp>P</scp> arkinson's Disease Brain is Region Dependent. Brain Pathology, 2014, 24, 584-598.	2.1	73
256	Microspectroscopy (μFTIR) Reveals Co-localization of Lipid Oxidation and Amyloid Plaques in Human Alzheimer Disease Brains. Analytical Chemistry, 2014, 86, 12047-12054.	3.2	87
257	Tubers from patients with tuberous sclerosis complex are characterized by changes in microtubule biology through <scp>ROCK2</scp> signalling. Journal of Pathology, 2014, 233, 247-257.	2.1	7
258	Dietary Lipid Unsaturation Influences Survival and Oxidative Modifications of an Amyotrophic Lateral Sclerosis Model in a Gender-Specific Manner. NeuroMolecular Medicine, 2014, 16, 669-685.	1.8	12
259	Huntington's disease is a four-repeat tauopathy with tau nuclear rods. Nature Medicine, 2014, 20, 881-885.	15.2	183
260	Cannabis-Based Medicine Reduces Multiple Pathological Processes in AβPP/PS1 Mice. Journal of Alzheimer's Disease, 2014, 43, 977-991.	1.2	110
261	LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity. Human Molecular Genetics, 2014, 23, 6779-6796.	1.4	139
262	Large-scale analysis of posttranslational modifications in the hippocampus of patients with Alzheimer's disease using pl shift and label-free quantification without enrichment. Analytical and Bioanalytical Chemistry, 2014, 406, 5433-5446.	1.9	5
263	Increased SP4 and SP1 transcription factor expression in the postmortem hippocampus of chronic schizophrenia. Journal of Psychiatric Research, 2014, 58, 189-196.	1.5	23
264	Mitochondrial dysfunction and oxidative damage cooperatively fuel axonal degeneration in X-linked adrenoleukodystrophy. Biochimie, 2014, 98, 143-149.	1.3	42
265	Mitochondrial dysfunction in central nervous system white matter disorders. Glia, 2014, 62, 1878-1894.	2.5	52
266	Altered lipid composition in cortical lipid rafts occurs at early stages of sporadic Alzheimer's disease and facilitates APP/BACE1 interactions. Neurobiology of Aging, 2014, 35, 1801-1812.	1.5	116
267	Increased striatal adenosine A2A receptor levels is an early event in Parkinson's disease-related pathology and it is potentially regulated by miR-34b. Neurobiology of Disease, 2014, 69, 206-214.	2.1	91
268	Biophysical Alterations in Lipid Rafts from Human Cerebral Cortex Associate with Increased BACE1/AβPP Interaction in Early Stages of Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 1185-1198.	1.2	65
269	Type-1 Cannabinoid Receptor Activity During Alzheimer's Disease Progression. Journal of Alzheimer's Disease, 2014, 42, 761-766.	1.2	54
270	O4-11-05: A PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLASMA REPLACEMENT WITH 5% ALBUMIN IN BETA-AMYLOID PEPTIDE CLEARANCE IN CEREBROSPINAL FLUID, AND ITS EFFECTS IN PATIENTS WITH MILD-MODERATE ALZHEIMER'S DISEASE. , 2014, 10, P274-P274.		0

#	Article	IF	CITATIONS
271	Brain Banking. , 2014, , 467-473.		12
272	Concomitant pathologies I. , 2014, , 274-291.		0
273	Dysregulation of brain olfactory and taste receptors in AD, PSP and CJD, and AD-related model. Neuroscience, 2013, 248, 369-382.	1.1	68
274	Reduced striatal ecto-nucleotidase activity in schizophrenia patients supports the "adenosine hypothesis― Purinergic Signalling, 2013, 9, 599-608.	1.1	27
275	CB2 Cannabinoid Receptor Agonist Ameliorates Alzheimer-Like Phenotype in AβPP/PS1 Mice. Journal of Alzheimer's Disease, 2013, 35, 847-858.	1.2	167
276	Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathologica, 2013, 126, 537-544.	3.9	168
277	Kidins220 accumulates with tau in human Alzheimer's disease and related models: modulation of its calpain-processing by GSK3β/PP1 imbalance. Human Molecular Genetics, 2013, 22, 466-482.	1.4	32
278	Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy. Human Molecular Genetics, 2013, 22, 3296-3305.	1.4	95
279	Neuropathology of the hippocampus in FTLDâ€Tau with Pick bodies: a study of the BrainNet Europe Consortium. Neuropathology and Applied Neurobiology, 2013, 39, 166-178.	1.8	54
280	It may be possible to delay the onset of neurodegenerative diseases with an immunosuppressive drug (rapamycin). Expert Opinion on Biological Therapy, 2013, 13, 1215-1219.	1.4	14
281	PrP ^C regulates epidermal growth factor receptor function and cell shape dynamics in Neuro2a cells. Journal of Neurochemistry, 2013, 127, 124-138.	2.1	33
282	Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy. Brain, 2013, 136, 2432-2443.	3.7	69
283	Oxidative stress regulates the ubiquitin–proteasome system and immunoproteasome functioning in a mouse model of X-adrenoleukodystrophy. Brain, 2013, 136, 891-904.	3.7	39
284	Upregulation of a small vault RNA (svtRNA2-1a) is an early event in Parkinson disease and induces neuronal dysfunction. RNA Biology, 2013, 10, 1093-1106.	1.5	44
285	Cyclophilin D as a potential target for antioxidants in neurodegeneration: the X-ALD case. Biological Chemistry, 2013, 394, 621-629.	1.2	5
286	Secretory Sorting Receptors Carboxypeptidase <scp>E</scp> and Secretogranin <scp>III</scp> in Amyloid I²â€Associated Neural Degeneration in <scp>A</scp> lzheimer's Disease. Brain Pathology, 2013, 23, 274-284.	2.1	38
287	PrP mRNA and protein expression in brain and PrPcin CSF in Creutzfeldt-Jakob disease MM1 and VV2. Prion, 2013, 7, 383-393.	0.9	45
288	Functional Genomics Reveals Dysregulation of Cortical Olfactory Receptors in Parkinson Disease: Novel Putative Chemoreceptors in the Human Brain. Journal of Neuropathology and Experimental Neurology, 2013, 72, 524-539.	0.9	111

ISIDRE FERRER

#	Article	IF	CITATIONS
289	Characterization of Thornâ€Shaped Astrocytes in White Matter of Temporal Lobe in <scp>A</scp> lzheimer's Disease Brains. Brain Pathology, 2013, 23, 144-153.	2.1	25
290	Amyloid-Precursor-Protein-Lowering Small Molecules for Disease Modifying Therapy of Alzheimer's Disease. PLoS ONE, 2013, 8, e82255.	1.1	6
291	Oxidative stress modulates mitochondrial failure and cyclophilin D function in X-linked adrenoleukodystrophy. Brain, 2012, 135, 3584-3598.	3.7	78
292	Evidence for Premature Lipid Raft Aging in APP/PS1 Double-Transgenic Mice, a Model of Familial Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2012, 71, 868-881.	0.9	69
293	Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study. Acta Neuropathologica, 2012, 124, 893-903.	3.9	110
294	Amyloid Generation and Dysfunctional Immunoproteasome Activation with Disease Progression in Animal Model of Familial Alzheimer's Disease. Brain Pathology, 2012, 22, 636-653.	2.1	95
295	Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. Acta Neuropathologica, 2012, 124, 517-529.	3.9	184
296	Histone tail acetylation in brain occurs in an unpredictable fashion after death. Cell and Tissue Banking, 2012, 13, 597-606.	0.5	8
297	The need to unify neuropathological assessments of vascular alterations in the ageing brain. Experimental Gerontology, 2012, 47, 825-833.	1.2	57
298	α-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience, 2012, 200, 106-119.	1.1	108
299	Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Progress in Neurobiology, 2012, 97, 38-51.	2.8	153
300	Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: A paradigm for multifactorial neurodegenerative diseases?. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 1475-1488.	1.8	84
301	Parkinson's Disease DJ-1 L166P Alters rRNA Biogenesis by Exclusion of TTRAP from the Nucleolus and Sequestration into Cytoplasmic Aggregates via TRAF6. PLoS ONE, 2012, 7, e35051.	1.1	51
302	Region Specific Vulnerability to Lipid Peroxidation in the Human Central Nervous System. , 2012, , .		3
303	Synthesis of triheptanoin and formulation as a solid diet for rodents. European Journal of Lipid Science and Technology, 2012, 114, 889-895.	1.0	5
304	Brain banks as key part of biochemical and molecular studies on cerebral cortex involvement in Parkinson's disease. FEBS Journal, 2012, 279, 1167-1176.	2.2	30
305	Neurochemistry and the non-motor aspects of PD. Neurobiology of Disease, 2012, 46, 508-526.	2.1	73
306	Neuronal Hemoglobin is Reduced in Alzheimer's Disease, Argyrophilic Grain Disease, Parkinson's Disease, and Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2011, 23, 537-550.	1.2	86

#	Article	IF	CITATIONS
307	Clinical and myopathological evaluation of early- and late-onset subtypes of myofibrillar myopathy. Neuromuscular Disorders, 2011, 21, 533-542.	0.3	135
308	Severe Alterations in Lipid Composition of Frontal Cortex Lipid Rafts from Parkinson's Disease and Incidental Parkinson's Disease. Molecular Medicine, 2011, 17, 1107-1118.	1.9	308
309	Molecular mechanisms of MLC1 and GLIALCAM mutations in megalencephalic leukoencephalopathy with subcortical cysts. Human Molecular Genetics, 2011, 20, 3266-3277.	1.4	80
310	Neuropathology and Neurochemistry of Nonmotor Symptoms in Parkinson's Disease. Parkinson's Disease, Parkinson's Disease, 2011, 2011, 1-13.	0.6	51
311	Mitochondrial Dysfunction and Oxidative and Endoplasmic Reticulum Stress in Argyrophilic Grain Disease. Journal of Neuropathology and Experimental Neurology, 2011, 70, 253-263.	0.9	18
312	Gerstmann-Straüssler-Scheinker PRNP P102L-129V mutation. Translational Neuroscience, 2011, 2, .	0.7	5
313	Methyl- and acetyltransferases are stable epigenetic markers postmortem. Cell and Tissue Banking, 2011, 12, 289-297.	0.5	12
314	Cell stress induces TDP-43 pathological changes associated with ERK1/2 dysfunction: implications in ALS. Acta Neuropathologica, 2011, 122, 259-270.	3.9	92
315	Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease. Journal of Neural Transmission, 2011, 118, 821-839.	1.4	156
316	Distribution of lipids in human brain. Analytical and Bioanalytical Chemistry, 2011, 401, 89-101.	1.9	52
317	Anatomical Distribution of Lipids in Human Brain Cortex by Imaging Mass Spectrometry. Journal of the American Society for Mass Spectrometry, 2011, 22, 329-338.	1.2	44
318	Antioxidants halt axonal degeneration in a mouse model of Xâ€adrenoleukodystrophy. Annals of Neurology, 2011, 70, 84-92.	2.8	122
319	Oxidative Damage Compromises Energy Metabolism in the Axonal Degeneration Mouse Model of X-Adrenoleukodystrophy. Antioxidants and Redox Signaling, 2011, 15, 2095-2107.	2.5	78
320	Neuroprotective role of PrP ^C against kainate-induced epileptic seizures and cell death depends on the modulation of JNK3 activation by GluR6/7–PSD-95 binding. Molecular Biology of the Cell, 2011, 22, 3041-3054.	0.9	59
321	General Aspects and Neuropathology of Xâ€Linked Adrenoleukodystrophy. Brain Pathology, 2010, 20, 817-830.	2.1	112
322	Foreword. Brain Pathology, 2010, 20, 815-816.	2.1	3
323	Lipid Alterations in Lipid Rafts from Alzheimer's Disease Human Brain Cortex. Journal of Alzheimer's Disease, 2010, 19, 489-502.	1.2	235
324	Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment. Acta Neuropathologica, 2010, 120, 155-167.	3.9	25

#	Article	IF	CITATIONS
325	Depletion of oxidative and endoplasmic reticulum stress regulators in Pick disease. Free Radical Biology and Medicine, 2010, 48, 1302-1310.	1.3	13
326	DNA methylation regulates adenosine A _{2A} receptor cell surface expression levels. Journal of Neurochemistry, 2010, 112, 1273-1285.	2.1	38
327	Mitochondrial ATP‣ynthase in the Entorhinal Cortex Is a Target of Oxidative Stress at Stages I/II of Alzheimer's Disease Pathology. Brain Pathology, 2010, 20, 222-233.	2.1	127
328	Protein Targets of Oxidative Damage in Human Neurodegenerative Diseases with Abnormal Protein Aggregates. Brain Pathology, 2010, 20, 281-297.	2.1	184
329	Chaperone-Mediated Autophagy Markers in Parkinson Disease Brains. Archives of Neurology, 2010, 67, 1464-72.	4.9	440
330	PINK1-linked parkinsonism is associated with Lewy body pathology. Brain, 2010, 133, 1128-1142.	3.7	223
331	Effects of Antemortem and Postmortem Variables on Human Brain mRNA Quality: A BrainNet Europe Study. Journal of Neuropathology and Experimental Neurology, 2010, 69, 70-81.	0.9	139
332	A Novel <i>PRNP Y218N</i> Mutation in Gerstmann-Strässler-Scheinker Disease With Neurofibrillary Degeneration. Journal of Neuropathology and Experimental Neurology, 2010, 69, 789-800.	0.9	46
333	Cognitive impairment of vascular origin: Neuropathology of cognitive impairment of vascular origin. Journal of the Neurological Sciences, 2010, 299, 139-149.	0.3	62
334	Modification of brain lipids but not phenotype in α-synucleinopathy transgenic mice by long-term dietary n-3 fatty acids. Neurochemistry International, 2010, 56, 318-328.	1.9	16
335	Aβ accumulation in choroid plexus is associated with mitochondrial-induced apoptosis. Neurobiology of Aging, 2010, 31, 1569-1581.	1.5	63
336	DNA Methylation of Alzheimer Disease and Tauopathy-Related Genes in Postmortem Brain. Journal of Neuropathology and Experimental Neurology, 2009, 68, 880-891.	0.9	162
337	Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies. Free Radical Biology and Medicine, 2009, 46, 1574-1580.	1.3	127
338	Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases. Journal of Neuroscience Research, 2009, 87, 1002-1013.	1.3	50
339	Neuropathology of Parkinson's disease with the R1441G mutation in <i>LRRK2</i> . Movement Disorders, 2009, 24, 1998-2001.	2.2	60
340	LRRK2 and neurodegeneration. Acta Neuropathologica, 2009, 117, 227-246.	3.9	62
341	Staging/typing of Lewy body related α-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 635-652.	3.9	249
342	Oxidative stress damage and oxidative stress responses in the choroid plexus in Alzheimer's disease. Acta Neuropathologica, 2009, 118, 497-504.	3.9	60

#	Article	IF	CITATIONS
343	Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease. Journal of Bioenergetics and Biomembranes, 2009, 41, 425-431.	1.0	159
344	pH measurement as quality control on human <i>post mortem</i> brain tissue: a study of the BrainNet Europe consortium. Neuropathology and Applied Neurobiology, 2009, 35, 329-337.	1.8	93
345	Delineation of Early Changes in Cases with Progressive Supranuclear Palsy‣ike Pathology. Astrocytes in Striatum are Primary Targets of Tau Phosphorylation and GFAP Oxidation. Brain Pathology, 2009, 19, 177-187.	2.1	44
346	Inter‣aboratory Assessment of PrP ^{Sc} Typing in Creutzfeldt–Jakob Disease: A Western Blot Study within the NeuroPrion Consortium. Brain Pathology, 2009, 19, 384-391.	2.1	50
347	Unexpected expression of α- and β-globin in mesencephalic dopaminergic neurons and glial cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15454-15459.	3.3	240
348	Early involvement of the cerebral cortex in Parkinson's disease: Convergence of multiple metabolic defects. Progress in Neurobiology, 2009, 88, 89-103.	2.8	92
349	Cell Death and Learning Impairment in Mice Caused by in Vitro Modified Pro-NGF Can Be Related to Its Increased Oxidative Modifications in Alzheimer Disease. American Journal of Pathology, 2009, 175, 2574-2585.	1.9	31
350	TAR DNA-Binding Protein 43 Accumulation in Protein Aggregate Myopathies. Journal of Neuropathology and Experimental Neurology, 2009, 68, 262-273.	0.9	83
351	Expression of mutant ubiquitin (UBB ⁺¹) and p62 in myotilinopathies and desminopathies. Neuropathology and Applied Neurobiology, 2008, 34, 76-87.	1.8	48
352	Brain banks: benefits, limitations and cautions concerning the use of post-mortem brain tissue for molecular studies. Cell and Tissue Banking, 2008, 9, 181-194.	0.5	151
353	Glycolitic enzymes are targets of oxidation in aged human frontal cortex and oxidative damage of these proteins is increased in progressive supranuclear palsy. Journal of Neural Transmission, 2008, 115, 59-66.	1.4	29
354	Inter-laboratory comparison of neuropathological assessments of β-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathologica, 2008, 115, 533-546.	3.9	86
355	Dystrophic neurites of senile plaques in Alzheimer's disease are deficient in cytochrome c oxidase. Acta Neuropathologica, 2008, 116, 261-268.	3.9	66
356	Assessing quantitative postâ€nortem changes in the gray matter of the human frontal cortex proteome by 2â€Ð DIGE. Proteomics, 2008, 8, 1276-1291.	1.3	64
357	<i>Maillard Reaction versus Other Nonenzymatic Modifications in Neurodegenerative Processes</i> . Annals of the New York Academy of Sciences, 2008, 1126, 315-319.	1.8	15
358	RESEARCH ARTICLE: Upâ€regulation of Adenosine Receptors in the Frontal Cortex in Alzheimer's Disease. Brain Pathology, 2008, 18, 211-219.	2.1	147
359	Staging of Neurofibrillary Pathology in Alzheimer's Disease: A Study of the BrainNet Europe Consortium. Brain Pathology, 2008, 18, 484-496.	2.1	361
360	Proteomic and oxidative stress analysis in human brain samples of Huntington disease. Free Radical Biology and Medicine, 2008, 45, 667-678.	1.3	250

#	Article	IF	CITATIONS
361	Increased oxidation, glycoxidation, and lipoxidation of brain proteins in prion disease. Free Radical Biology and Medicine, 2008, 45, 1159-1166.	1.3	74
362	Early α-synuclein lipoxidation in neocortex in Lewy body diseases. Neurobiology of Aging, 2008, 29, 408-417.	1.5	67
363	Phosphorylation of tau and α-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related α-synucleinopathies. Neuroscience, 2008, 15 913-923.	52,1.1	129
364	Molecular pathology of myofibrillar myopathies. Expert Reviews in Molecular Medicine, 2008, 10, e25.	1.6	67
365	Mixed Brain Pathologies in Dementia: The BrainNet Europe Consortium Experience. Dementia and Geriatric Cognitive Disorders, 2008, 26, 343-350.	0.7	148
366	Argyrophilic grain disease. Brain, 2008, 131, 1416-1432.	3.7	183
367	Neuropathology of Hereditary Forms of Frontotemporal Dementia and Parkinsonism. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 393-414.	1.0	10
368	Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Human Molecular Genetics, 2008, 17, 1762-1773.	1.4	181
369	Type-Dependent Oxidative Damage in Frontotemporal Lobar Degeneration: Cortical Astrocytes Are Targets of Oxidative Damage. Journal of Neuropathology and Experimental Neurology, 2008, 67, 1122-1136.	0.9	46
370	Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain, 2007, 130, 3111-3123.	3.7	296
371	Desmin Is Oxidized and Nitrated in Affected Muscles in Myotilinopathies and Desminopathies. Journal of Neuropathology and Experimental Neurology, 2007, 66, 711-723.	0.9	33
372	Brain Protein Preservation Largely Depends on the Postmortem Storage Temperature. Journal of Neuropathology and Experimental Neurology, 2007, 66, 35-46.	0.9	151
373	Phenotypic patterns of desminopathy associated with three novel mutations in the desmin gene. Neuromuscular Disorders, 2007, 17, 443-450.	0.3	50
374	Abnormal levels of prohibitin and ATP synthase in the substantia nigra and frontal cortex in Parkinson's disease. Neuroscience Letters, 2007, 415, 205-209.	1.0	66
375	Target Genes of Neuron-Restrictive Silencer Factor Are Abnormally Up-Regulated in Human Myotilinopathy. American Journal of Pathology, 2007, 171, 1312-1323.	1.9	30
376	Effects of Formalin Fixation, Paraffin Embedding, and Time of Storage on DNA Preservation in Brain Tissue: A BrainNet Europe Study. Brain Pathology, 2007, 17, 297-303.	2.1	127
377	Oxidative Stress in Desminopathies and Myotilinopathies: A Link between Oxidative Damage and Abnormal Protein Aggregation. Brain Pathology, 2007, 17, 377-388.	2.1	43
378	Aquaporin expression in the cerebral cortex is increased at early stages of Alzheimer disease. Brain Research, 2007, 1128, 164-174.	1.1	80

#	Article	IF	CITATIONS
379	Aquaporin 1 and aquaporin 4 overexpression in bovine spongiform encephalopathy in a transgenic murine model and in cattle field cases. Brain Research, 2007, 1175, 96-106.	1.1	19
380	Late-onset frontotemporal dementia associated with a novel PGRN mutation. Journal of Neural Transmission, 2007, 114, 1051-1054.	1.4	13
381	Pro-NGF from Alzheimer's Disease and Normal Human Brain Displays Distinctive Abilities to Induce Processing and Nuclear Translocation of Intracellular Domain of p75NTR and Apoptosis. American Journal of Pathology, 2006, 169, 119-131.	1.9	74
382	TaqMan PCR assay in the control of RNA normalization in human post-mortem brain tissue. Neurochemistry International, 2006, 49, 276-284.	1.9	71
383	Abnormal Sp1 transcription factor expression in Alzheimer disease and tauopathies. Neuroscience Letters, 2006, 397, 30-34.	1.0	62
384	Low molecular weight species of tau in Alzheimer's disease are dependent on tau phosphorylation sites but not on delayed post-mortem delay in tissue processing. Neuroscience Letters, 2006, 399, 106-110.	1.0	18
385	Oxidation, glycoxidation, lipoxidation, nitration, and responses to oxidative stress in the cerebral cortex in Creutzfeldt–Jakob disease. Neurobiology of Aging, 2006, 27, 1807-1815.	1.5	76
386	Different early pathogenesis in myotilinopathy compared to primary desminopathy. Neuromuscular Disorders, 2006, 16, 361-367.	0.3	29
387	Involvement of Clusterin and the Aggresome in Abnormal Protein Deposits in Myofibrillar Myopathies and Inclusion Body Myositis. Brain Pathology, 2006, 15, 101-108.	2.1	36
388	Glial fibrillary acidic protein is a major target of glycoxidative and lipoxidative damage in Pick's disease. Journal of Neurochemistry, 2006, 99, 177-185.	2.1	48
389	Lysosome-associated membrane protein 1 (LAMP-1) in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2006, 32, 505-516.	1.8	72
390	Increased expression of water channel aquaporin 1 and aquaporin 4 in Creutzfeldt-Jakob disease and in bovine spongiform encephalopathy-infected bovine-PrP transgenic mice. Acta Neuropathologica, 2006, 112, 573-585.	3.9	68
391	Apoptosis: Future Targets for Neuroprotective Strategies. Cerebrovascular Diseases, 2006, 21, 9-20.	0.8	74
392	Inactivation of the peroxisomal ABCD2 transporter in the mouse leads to late-onset ataxia involving mitochondria, Golgi and endoplasmic reticulum damage. Human Molecular Genetics, 2005, 14, 3565-3577.	1.4	90
393	Proteins in Human Brain Cortex Are Modified by Oxidation, Glycoxidation, and Lipoxidation. Journal of Biological Chemistry, 2005, 280, 21522-21530.	1.6	246
394	Current Advances on Different Kinases Involved in Tau Phosphorylation, and Implications in Alzheimers Disease and Tauopathies. Current Alzheimer Research, 2005, 2, 3-18.	0.7	281
395	A novel mutation (K317M) in the MAPT gene causes FTDP and motor neuron disease. Neurology, 2005, 64, 1578-1585.	1.5	97
396	Evidence of Oxidative Stress in the Neocortex in Incidental Lewy Body Disease. Journal of Neuropathology and Experimental Neurology, 2005, 64, 816-830.	0.9	222

#	Article	IF	CITATIONS
397	Myotilinopathy: refining the clinical and myopathological phenotype. Brain, 2005, 128, 2315-2326.	3.7	146
398	Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiology of Disease, 2005, 20, 392-400.	2.1	152
399	Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. Neurobiology of Disease, 2005, 20, 814-822.	2.1	163
400	α-Synuclein binding to rab3a in multiple system atrophy. Neuroscience Letters, 2005, 380, 170-175.	1.0	43
401	Pro-NGF Isolated from the Human Brain Affected by Alzheimer's Disease Induces Neuronal Apoptosis Mediated by p75NTR. American Journal of Pathology, 2005, 166, 533-543.	1.9	149
402	Characterization of a double (amyloid precursor protein-tau) transgenic: Tau phosphorylation and aggregation. Neuroscience, 2005, 130, 339-347.	1.1	78
403	Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Human Molecular Genetics, 2004, 13, 2997-3006.	1.4	170
404	Selective PrP-like protein, doppel immunoreactivity in dystrophic neurites of senile plaques in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2004, 30, 329-337.	1.8	12
405	Expression of stress-activated kinases c-Jun N-terminal kinase (SAPK/JNK-P) and p38 kinase (p38-P), and tau hyperphosphorylation in neurites surrounding βA plaques in APP Tg2576 mice. Neuropathology and Applied Neurobiology, 2004, 30, 491-502.	1.8	78
406	Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease. Brain Pathology, 2004, 14, 11-20.	2.1	531
407	Small deletions disturb desmin architecture leading to breakdown of muscle cells and development of skeletal or cardioskeletal myopathy. Human Genetics, 2004, 114, 306-313.	1.8	59
408	Active stress kinase p38 enhances and perpetuates abnormal tau phosphorylation and deposition in Pick?s disease. Acta Neuropathologica, 2004, 107, 185-189.	3.9	30
409	Clusterin solubility and aggregation in Creutzfeldt-Jakob disease. Acta Neuropathologica, 2004, 108, 295-301.	3.9	49
410	A series of West European patients with severe cardiac and skeletal myopathy associated with a de novo R406W mutation in desmin. Journal of Neurology, 2004, 251, 143-149.	1.8	53
411	Stress kinases involved inTau phosphorylation in alzheimer's disease, tauopathies and APP transgenic mice. Neurotoxicity Research, 2004, 6, 469-475.	1.3	46
412	Desmin-related myopathy: clinical, electrophysiological, radiological, neuropathological and genetic studies. Journal of the Neurological Sciences, 2004, 219, 125-137.	0.3	72
413	Abnormal α-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease. Neurobiology of Disease, 2004, 16, 92-97.	2.1	85
414	Ubiquitin-negative mini-pick-like bodies in the dentate gyrus in p301l tauopathy. Journal of Alzheimer's Disease, 2004, 5, 445-454.	1.2	16

#	Article	IF	CITATIONS
415	Proteasomal Expression, Induction of Immunoproteasome Subunits, and Local MHC Class I Presentation in Myofibrillar Myopathy and Inclusion Body Myositis. Journal of Neuropathology and Experimental Neurology, 2004, 63, 484-498.	0.9	84
416	Abnormal α-Synuclein Interactions with Rab Proteins in α-Synuclein A30P Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 2004, 63, 302-313.	0.9	93
417	Abnormal Metabotropic Glutamate Receptor Expression and Signaling in the Cerebral Cortex in Diffuse Lewy Body Disease is Associated with Irregular αâ€ S ynuclein/Phospholipase C (PLCβ ₁) Interactions. Brain Pathology, 2004, 14, 388-398.	2.1	65
418	Early modifications in the expression of mitogen-activated protein kinase (MAPK/ERK), stress-activated kinases SAPK/JNK and p38, and their phosphorylated substrates following focal cerebral ischemia. Acta Neuropathologica, 2003, 105, 425-437.	3.9	109
419	Expression of the intermediate filament protein synemin in myofibrillar myopathies and other muscle diseases. Acta Neuropathologica, 2003, 106, 1-7.	3.9	29
420	GluR2/3, NMDA?1 and GABAA receptors in Creutzfeldt-Jakob disease. Acta Neuropathologica, 2003, 106, 311-318.	3.9	22
421	Primary progressive aphasia as the initial manifestation of corticobasal degeneration and unusual tauopathies. Acta Neuropathologica, 2003, 106, 419-435.	3.9	67
422	Tau phosphorylation and kinase activation in familial tauopathy linked to deln296 mutation. Neuropathology and Applied Neurobiology, 2003, 29, 23-34.	1.8	44
423	Caspase-dependent and caspase-independent signalling of apoptosis in the penumbra following middle cerebral artery occlusion in the adult rat. Neuropathology and Applied Neurobiology, 2003, 29, 472-481.	1.8	94
424	Signaling of Cell Death and Cell Survival Following Focal Cerebral Ischemia: Life and Death Struggle in the Penumbra. Journal of Neuropathology and Experimental Neurology, 2003, 62, 329-339.	0.9	324
425	Phosphorylated Protein Kinases Associated with Neuronal and Glial <i>Tau</i> Deposits in Argyrophilic Grain Disease. Brain Pathology, 2003, 13, 62-78.	2.1	52
426	A ₁ Adenosine Receptors Accumulate in Neurodegenerative Structures in Alzheimer's Disease and Mediate Both Amyloid Precursor Protein Processing and Tau Phosphorylation and Translocation. Brain Pathology, 2003, 13, 440-451.	2.1	150
427	Brainstem dysgenesis: report of five patients with congenital hypotonia, multiple cranial nerve involvement, and ocular motor apraxia. Developmental Medicine and Child Neurology, 2003, 45, 489-493.	1.1	33
428	Active, phosphorylation-dependent MAP kinases, MAPK/ERK, SAPK/JNK and p38, and specific transcription factor substrates are differentially expressed following systemic administration of kainic acid to the adult rat. Acta Neuropathologica, 2002, 103, 391-407.	3.9	64
429	Abnormal synaptic protein expression and cell death in murine scrapie. Acta Neuropathologica, 2002, 103, 615-626.	3.9	79
430	Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathologica, 2002, 104, 583-591.	3.9	174
431	Differential expression of phosphorylated translation initiation factor 2 alpha in Alzheimer's disease and Creutzfeldt-Jakob's disease. Neuropathology and Applied Neurobiology, 2002, 28, 441-451.	1.8	37
432	Synaptic pathology and cell death in the cerebellum in Creutzfeldt-Jakob disease. Cerebellum, 2002, 1, 213-222.	1.4	73

#	Article	IF	CITATIONS
433	Differential expression of active, phosphorylation-dependent MAP kinases, MAPK/ERK, SAPK/JNK and p38, and specific transcription factor substrates following quinolinic acid excitotoxicity in the rat. Molecular Brain Research, 2001, 94, 48-58.	2.5	51
434	Connexin 31 (GJB3) is expressed in the peripheral and auditory nerves and causes neuropathy and hearing impairment. Human Molecular Genetics, 2001, 10, 947-952.	1.4	109
435	Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies. Journal of Neural Transmission, 2001, 108, 1383-1396.	1.4	146
436	Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. Journal of Neural Transmission, 2001, 108, 1397-1415.	1.4	188
437	Brain-derived neurotrophic factor reduces cortical cell death by ischemia after middle cerebral artery occlusion in the rat. Acta Neuropathologica, 2001, 101, 229-238.	3.9	146
438	Fas and Fas ligand expression in Alzheimer's disease. Acta Neuropathologica, 2001, 102, 121-131.	3.9	46
439	Phosphorylated c-MYC expression in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Neuropathology and Applied Neurobiology, 2001, 27, 343-351.	1.8	57
440	Plasma Homocysteine Levels in Type 1 Diabetic Patients. Diabetes Care, 2001, 24, 970-971.	4.3	0
441	Phosphorylated Map Kinase (ERK1, ERK2) Expression is Associated with Early Tau Deposition in Neurones and Glial Cells, but not with Increased Nuclear DNA Vulnerability and Cell Death, in Alzheimer Disease, Pick's Disease, Progressive Supranuclear Palsy and Corticobasal Degeneration. Brain Pathology, 2001, 11, 144-158.	2.1	206
442	Bcl-2 and Bax immunohistochemistry in denervation-reinnervation and necrosis-regeneration of rat skeletal muscles. Muscle and Nerve, 2000, 23, 1862-1867.	1.0	22
443	Brain-derived neurotrophic factor in patients with frontotemporal dementia. Neuroscience Letters, 2000, 279, 33-36.	1.0	14
444	Prion protein deposition and abnormal synaptic protein expression in the cerebellum in Creutzfeldt–Jakob disease. Neuroscience, 2000, 97, 715-726.	1.1	59
445	c-Jun/AP-1 (N) expression and apoptosis. Neuroscience, 2000, 96, 447-448.	1.1	8
446	N-myc and c-myc expression in Alzheimer disease, Huntington disease and Parkinson disease. Molecular Brain Research, 2000, 77, 270-276.	2.5	57
447	BDNF and Full-length and Truncated TrkB Expression in Alzheimer Disease. Implications in Therapeutic Strategies. Journal of Neuropathology and Experimental Neurology, 1999, 58, 729-739.	0.9	350
448	Nuclear DNA fragmentation in Creutzfeldt-Jakob disease: does a mere positive in situ nuclear end-labeling indicate apoptosis?. Acta Neuropathologica, 1999, 97, 5-12.	3.9	46
449	Role of caspases in ionizing radiation-induced apoptosis in the developing cerebellum. , 1999, 41, 549-558.		27
450	Expression of Proteins Linked to Exocytosis and Neurotransmission in Patients with Creutzfeldt–Jakob Disease. Neurobiology of Disease, 1999, 6, 92-100.	2.1	46

#	Article	IF	CITATIONS
451	Neurons and Their Dendrites in Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 1999, 10, 55-60.	0.7	87
452	Multiple neurotrophic signals converge in surviving CA1 neurons of the gerbil hippocampus following transient forebrain ischemia. , 1998, 394, 416-430.		32
453	Bcl-2, Bax, and Bcl-x expression in the CA1 area of the hippocampus following transient forebrain ischemia in the adult gerbil. Experimental Brain Research, 1998, 121, 167-173.	0.7	44
454	Brain-derived neurotrophic factor does not prevent ionizing radiation-induced apoptosis in the developing rat brain. Neuroscience Letters, 1998, 257, 85-88.	1.0	1
455	Dystrophic Neurites of Senile Plaques are Defective in Proteins Involved in Exocytosis and Neurotransmission. Journal of Neuropathology and Experimental Neurology, 1998, 57, 218-225.	0.9	43
456	BDNF Upâ€Regulates TrkB Protein and Prevents the Death of CA1 Neurons Following Transient Forebrain Ischemia. Brain Pathology, 1998, 8, 253-261.	2.1	79
457	Multiple neurotrophic signals converge in surviving CA1 neurons of the gerbil hippocampus following transient forebrain ischemia. Journal of Comparative Neurology, 1998, 394, 416-30.	0.9	8
458	BDNF and TrkB Co-localize in CA1 Neurons Resistant to Transient Forebrain Ischemia in the Adult Gerbil. Journal of Neuropathology and Experimental Neurology, 1997, 56, 790-797.	0.9	23
459	Radiation-induced apoptosis in developing rats and kainic acid-induced excitotoxicity in adult rats are associated with distinctive morphological and biochemical c-Jun/AP-1 (N) expression. Neuroscience, 1997, 80, 449-458.	1.1	36
460	Ubiquitination of apoptotic cells in the developing cerebellum of the rat following ionizing radiation or methylazoxymethanol injection. Acta Neuropathologica, 1997, 93, 402-407.	3.9	10
461	Apoptosis is not the mechanism of cell death of muscle fibers in human muscular dystrophies and inflammatory myopathies. , 1997, 20, 1328-1330.		33
462	Kainic acid?induced excitotoxicity is associated with a complex c-Fos and c-Jun response which does not preclude either cell death or survival. Journal of Neurobiology, 1997, 33, 232-246.	3.7	40
463	Kainic acidâ \in "induced excitotoxicity is associated with a complex c-Fos and c-Jun response which does not preclude either cell death or survival. , 1997, 33, 232.		2
464	Transforming growth factor-α (TGF-α) and epidermal growth factor-receptor (EGF-R) immunoreactivity in normal and pathologic brain. Progress in Neurobiology, 1996, 49, 99-119.	2.8	85
465	CREB-1 and CREB-2 immunoreactivity in the rat brain. Brain Research, 1996, 712, 159-164.	1.1	16
466	Clinical and immunohistochemical comparison of <i>in vivo</i> injected antiâ€Hu and control IgG in the nervous system of the mouse. European Journal of Neurology, 1996, 3, 319-323.	1.7	4
467	Cell death in the normal developing brain, and following ionizing radiation, methyl-azoxymethanol acetate, and hypoxia-ischaemia in the rat. Neuropathology and Applied Neurobiology, 1996, 22, 489-494.	1.8	28
468	Amyloid deposition is associated with c-Jun expression in Alzheimer's disease and amyloid angiopathy. Neuropathology and Applied Neurobiology, 1996, 22, 521-526.	1.8	20

#	Article	IF	CITATIONS
469	Naturally Occurring (Programmed) and Radiation-induced Apoptosis are Associated with Selective c-Jun Expression in the Developing Rat Brain. European Journal of Neuroscience, 1996, 8, 1286-1298.	1.2	77
470	Thalamic and Basal Forebrain Afferents Modulate the Development of Parvalbumin and Calbindin D28k Immunoreactivity in the Barrel Cortex of the Rat. European Journal of Neuroscience, 1996, 8, 1522-1534.	1.2	42
471	Strong c-Jun immunoreactivity is associated with apoptotic cell death in human tumors of the central nervous system. Neuroscience Letters, 1996, 214, 49-52.	1.0	4
472	Both apoptosis and necrosis occur following intrastriatal administration of excitotoxins. Acta Neuropathologica, 1995, 90, 504-510.	3.9	82
473	Kainic Acid-induced Heat Shock Protein-70, mRNA and Protein Expression is Inhibited by MK-801 in Certain Rat Brain Regions. European Journal of Neuroscience, 1995, 7, 293-304.	1.2	55
474	Survival of parvalbumin-immunoreactive neurons in the gerbil hippocampus following transient forebrain ischemia does not depend on HSP-70 protein induction. Brain Research, 1995, 692, 41-46.	1.1	25
475	A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart. Human Molecular Genetics, 1995, 4, 1935-1944.	1.4	250
476	Amoeboid microglial response following X-ray-induced apoptosis in the neonatal rat brain. Neuroscience Letters, 1995, 193, 109-112.	1.0	13
477	Transforming growth factor-α immunoreactivity in the developing and adult brain. Neuroscience, 1995, 66, 189-199.	1.1	73
478	Both apoptosis and necrosis occur following intrastriatal administration of excitotoxins. Acta Neuropathologica, 1995, 90, 504-510.	3.9	7
479	Evidence of Nuclear DNA Fragmentation Following Hypoxiaâ€Ischemia in the Infant Rat Brain, and Transient Forebrain Ischemia in the Adult Gerbil. Brain Pathology, 1994, 4, 115-122.	2.1	150
480	Parvalbumin immunocytochemistry and calcium deposition in muscle fiber necrosis and subsequent regeneration following intramuscular injection of metoclopramide. Muscle and Nerve, 1994, 17, 494-499.	1.0	9
481	Postnatal development of parvalbumin immunoreactivity in the cerebral cortex of the cat. Journal of Comparative Neurology, 1994, 348, 133-149.	0.9	36
482	The Purkinje cell in olivopontocerebellar atrophy. A Golgi and immunocytochemical study. Neuropathology and Applied Neurobiology, 1994, 20, 38-46.	1.8	41
483	Parvalbumin and calbindin-D28k immunocytochemistry in human neocortical epileptic foci. Journal of the Neurological Sciences, 1994, 123, 18-25.	0.3	95
484	Effects of X-irradiation on Glial Cells in the Developing Rat Brain. International Journal of Radiation Biology, 1994, 66, 181-187.	1.0	6
485	Parvalbumin-immunoreactive cortical neurons in Creutzfeldt-Jakob disease. Annals of Neurology, 1993, 34, 864-866.	2.8	39
486	Distribution, morphological features, and synaptic connections of parvalbumin- and calbindin D28k-immunoreactive neurons in the human hippocampal formation. Journal of Comparative Neurology, 1993, 337, 208-230.	0.9	121

#	Article	IF	CITATIONS
487	Structure and pathogenesis of cortical nodules induced by prenatal X-irradiation in the rat. Acta Neuropathologica, 1993, 85, 205-12.	3.9	16
488	Radiosensitive populations and recovery in X-ray-induced apoptosis in the developing cerebellum. Acta Neuropathologica, 1993, 86, 491-500.	3.9	35
489	Experimentally induced laminar necrosis, status verrucosus, focal cortical dysplasia reminiscent of microgyria, and porencephaly in the rat. Experimental Brain Research, 1993, 94, 261-9.	0.7	36
490	Experimentally induced cortical malformations in rats. Child's Nervous System, 1993, 9, 403-407.	0.6	25
491	Primary central white matter degeneration in old dogs. Acta Neuropathologica, 1993, 86, 172-175.	3.9	28
492	A four-layered â€~lissencephalic' cortex induced by prenatal X-irradiation in the rat. Neuropathology and Applied Neurobiology, 1993, 19, 74-81.	1.8	13
493	Neuronal ectopic masses induced by prenatal irradiation in the rat. Virchows Archiv A, Pathological Anatomy and Histopathology, 1993, 422, 1-6.	1.4	15
494	Parvalbumin-immunoreactive dystrophic neurites and aberrant sprouts in the cerebral cortex of patients with Alzheimer's disease. Neuroscience Letters, 1993, 158, 163-166.	1.0	18
495	Calbindin D-28k and parvalbumin immunoreactivity in the frontal cortex in patients with frontal lobe dementia of non-Alzheimer type associated with amyotrophic lateral sclerosis Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 257-261.	0.9	45
496	Hepatic and Pulmonary Pneumocystosis During Primary Prophylaxis for Pneumocystis carinii Pneumonia with Dapsone/Pyrimethamine. Clinical Infectious Diseases, 1993, 16, 171-171.	2.9	9
497	Calbindin D-28k immunoreactivity in the temporal neocortex in patients with Alzheimer's disease. , 1993, 12, 53-8.		3
498	Calbindin immunoreactivity in normal human temporal neocortex. Brain Research, 1992, 572, 33-41.	1.1	53
499	Development of GABA-immunoreactivity in the neocortex of the mouse. Journal of Comparative Neurology, 1992, 326, 501-526.	0.9	134
500	Parvalbumin and calbindin immunoreactivity in the cerebral cortex of the hedgehog (Erinaceus) Tj ETQq0 0 0 rgBT	/Oyerlock	10 Tf 50 22
501	Dementia of frontal lobe type and amyotrophy. Behavioural Neurology, 1992, 5, 87-96.	1.1	3
502	Naturally occurring, postnatal cell death in the cerebral cortex of the micrencephalic rat induced by prenatal X-irradiation. Neuroscience Research, 1991, 12, 446-451.	1.0	10
503	Development of dendritic spines in the cerebral cortex of the micrencephalic rat following prenatal X-irradiation. Neuroscience Letters, 1991, 125, 183-186.	1.0	7
504	Unlayered polymicrogyria : structural and developmental aspects. Anatomy and Embryology, 1991, 184, 517-528.	1.5	56

#	Article	IF	CITATIONS
505	Dementia of frontal lobe type and motor neuron disease. A Golgi study of the frontal cortex Journal of Neurology, Neurosurgery and Psychiatry, 1991, 54, 932-934.	0.9	53
506	Neuronal alterations in patients with dementia: a Golgi study on biopsy samples. Neuroscience Letters, 1990, 114, 11-16.	1.0	78
507	Arteriolosclerotic leucoencephalopathy in the elderly and its relation to white matter lesions in Binswanger's disease, multi-infarct encephalopathy and Alzheimer's disease. Journal of the Neurological Sciences, 1990, 98, 37-50.	0.3	86
508	Studies with the Golgi method in central gangliogliomas and dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos disease). Histology and Histopathology, 1990, 5, 329-36.	0.5	7
509	Developmental aspects of the neocortex of the bat. Neuroscience Research, 1989, 6, 573-580.	1.0	4
510	FOCAL DENDRITIC SWELLINGS IN PURKINJE CELLS IN MUCOPOLYSACCHARIDOSES TYPES I, II AND III. A GOLGI AND ULTRASTRUCTURAL STUDY. Neuropathology and Applied Neurobiology, 1988, 14, 315-323.	1.8	24
511	Formation and growth of the cerebral convolutions. I. Postnatal development of the median-suprasylvian gyrus and adjoining sulci in the cat. Journal of Anatomy, 1988, 160, 89-100.	0.9	16
512	Purkinje cells in degenerative diseases of the cerebellum and its connections: a Golgi study. , 1988, 7, 22-8.		7
513	Dendritic Spine Anomalies in Fetal Alcohol Syndrome. Neuropediatrics, 1987, 18, 161-163.	0.3	59
514	Dégénérescence systématisée optico-cochléo-dentelée. Journal of Neurology, 1987, 234, 416-42	201.8	11
515	A Golgi study of the sixth layer of the cerebral cortex. I. The lissencephalic brain of Rodentia, Lagomorpha, Insectivora and Chiroptera. Journal of Anatomy, 1986, 145, 217-34.	0.9	43
516	Mixed carcinomatous neuropathy in patients with lung cancer and lymphoma. Acta Neurologica Scandinavica, 1983, 68, 40-48.	1.0	21
517	Potential Therapeutic Strategies to Prevent the Progression of Alzheimer to Disease States. , 0, , .		2
518	Tau Protein as a Biological Fluid Biomarker in Neurodegenerative Dementias. , 0, , .		5
519	Dysregulated Protein Phosphorylation in a Mouse Model of FTLD-Tau. Journal of Neuropathology and Experimental Neurology, 0, , .	0.9	3